AIM ImmunoTech reports positive year-end interim Phase 2 data
for Ampligen plus Imfinzi in metastatic pancreatic cancer, highlighting continued PFS/OS benefits, favorable safety, high quality of life and an updated corporate strategy presentation prioritizing Ampligen’s path toward Phase 3.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.